127 related articles for article (PubMed ID: 27967239)
21. ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.
Wang J; Rouse C; Jasper JS; Pendergast AM
Sci Signal; 2016 Feb; 9(413):ra12. PubMed ID: 26838548
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer-derived factors facilitate osteolytic bone metastasis.
Rose AA; Siegel PM
Bull Cancer; 2006 Sep; 93(9):931-43. PubMed ID: 16980236
[TBL] [Abstract][Full Text] [Related]
23. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
24. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
25. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
26. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
27. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4.
Nakamura ES; Koizumi K; Kobayashi M; Saitoh Y; Arita Y; Nakayama T; Sakurai H; Yoshie O; Saiki I
Clin Exp Metastasis; 2006; 23(1):9-18. PubMed ID: 16821125
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
29. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
30. The bone remodeling environment is a factor in breast cancer bone metastasis.
Ooi LL; Zheng Y; Stalgis-Bilinski K; Dunstan CR
Bone; 2011 Jan; 48(1):66-70. PubMed ID: 20472107
[TBL] [Abstract][Full Text] [Related]
31. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
32. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
33. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
34. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
[TBL] [Abstract][Full Text] [Related]
35. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
Sasaki S; Baba T; Nishimura T; Hayakawa Y; Hashimoto S; Gotoh N; Mukaida N
Cancer Lett; 2016 Aug; 378(1):23-32. PubMed ID: 27177471
[TBL] [Abstract][Full Text] [Related]
36. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior.
Sterling JA; Edwards JR; Martin TJ; Mundy GR
Bone; 2011 Jan; 48(1):6-15. PubMed ID: 20643235
[TBL] [Abstract][Full Text] [Related]
37. Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors.
Matteucci E; Maroni P; Luzzati A; Perrucchini G; Bendinelli P; Desiderio MA
Eur J Cancer; 2013 Jan; 49(1):231-44. PubMed ID: 22717556
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S; Goldstein RH; Scepansky EM; Rosenblatt M
Cancer Res; 2009 Nov; 69(22):8742-51. PubMed ID: 19887617
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer Derived Extracellular Vesicles in Bone Metastasis Induction and Their Clinical Implications as Biomarkers.
Taverna S; Giusti I; D'Ascenzo S; Pizzorno L; Dolo V
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
